ERBB2 and heart failure: Some oncological treatments are associated with cardiotoxicity and may directly increase the risk of AF (e.g. ibrutinib) or indirectly via the development of heart failure (e.g. anthracyclines, anti-HER2 therapies and tyrosine kinase inhibitors).